The present invention provides methods of treating a parasitic infection, a lymphoid
malignancy or an autoimmune disorder in a subject by administering to the subject
a therapeutically effective amount of an angiogenesis inhibitor compound comprising
a MetAP-2 inhibitory core coupled to a peptide.
